MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Type of Assessment:

Biomarkers for detecting malignant pleural mesothelioma: Protocol for a reanalysis of published data based on systematic reviews of diagnostic test accuracy.

Medicine 2019 June [Link] Zan X, Wang Y, Shi J, Zhao L, Zhao Y, Liu R, Zhou Y, Wan Y Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a highly invasive tumor caused primarily by asbestos exposure. In recent decades, the incidence of MPM has shown an increasing trend, posing a great threat to human health. […]

Comments Off on Biomarkers for detecting malignant pleural mesothelioma: Protocol for a reanalysis of published data based on systematic reviews of diagnostic test accuracy.

The Prevalence and Clinical Relevance of Non-expandable Lung in Malignant Pleural Mesothelioma: A Prospective, Single-Center Cohort Study of 229 Patients.

Annals of the American Thoracic Society 2019 June 12 [Link] Bibby AC, Halford P, De Fonseka D, Morley AJ, Smith S, Maskell NA Abstract RATIONALE: Non-expandable lung is a recognised phenomenon that can create management challenges in mesothelioma. Its prevalence and clinical importance are unknown. OBJECTIVE: The aim of this study was to describe the […]

Comments Off on The Prevalence and Clinical Relevance of Non-expandable Lung in Malignant Pleural Mesothelioma: A Prospective, Single-Center Cohort Study of 229 Patients.

Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database.

Journal of Thoracic Disease 2019 April [Link] Nelson DB, Rice DC, Mitchell KG, Tsao AS, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Gomez DR, Mehran RJ, Sepesi B Abstract BACKGROUND: Multimodality therapy may prolong survival among resectable malignant pleural mesothelioma (MPM). However, the role of adjuvant radiation remains controversial. We […]

Comments Off on Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database.

Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma.

Journal of Thoracic Disease 2019 April [Link] Rodríguez-Cid JR, García-Acevedo O, Benjamin-Contreras J, Bonilla-Molina D, Flores-Mariñelarena RR, Martínez-Barrera L, Alatorre-Alexander JA, Sanchez-Ríos CP, Flores-Soto MDR, Santillan-Doherty PJ, Peña-Mirabal ES Abstract BACKGROUND: Overexpression of estrogen receptors in malignant pleural mesothelioma has shown an independent relation with a better prognosis of survival, and the use of selective […]

Comments Off on Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma.

Health-related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.

Clinical Cancer Research 2019 June 7 [Link] Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Lena H, Rivière F, Monnet I, Gounant V, Janicot H, Gervais R, Locher C, Charton E, Morin F, Zalcman G, Westeel V Abstract PURPOSE: The IFCT-GFPC-0701 MAPS Phase III trial […]

Comments Off on Health-related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.

Biomarkers for malignant pleural mesothelioma: a meta-analysis.

Carcinogenesis 2019 June 5 [Link] Gillezeau C, van Gerwen M, Ramos J, Liu B, Flores R, Taioli E Abstract Malignant Pleural Mesothelioma (MPM) is a rare by aggressive cancer, and early detection is associated with better survival. Mesothelin, fibulin-3, and osteopontin have been suggested as screening biomarkers. The study conducted a meta-analysis of the mean […]

Comments Off on Biomarkers for malignant pleural mesothelioma: a meta-analysis.

Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT).

Clinical Cancer Research 2019 June 4 [Link] Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Hirano J, Namba Y, Ohe Y Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with poor […]

Comments Off on Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT).

Diagnostic Value of BAP1, GLUT-1 and Desmin Expression in the Discrimination Between Reactive Mesothelial Proliferation and Malignant Mesothelioma in Tissues and Effusions.

Cytopathology 2019 June 5 [Link] Önder S, Özogul E, Koksal D, Sarinc Ulasli S, Firat P, Emri S Abstract OBJECTIVE: The aim of this study was to investigate the utility of BAP1, GLUT-1 and desmin expression by immunohistochemistry in the discrimination between reactive and malignant mesothelial proliferations. METHODS: A total of 88 biopsies and 30 […]

Comments Off on Diagnostic Value of BAP1, GLUT-1 and Desmin Expression in the Discrimination Between Reactive Mesothelial Proliferation and Malignant Mesothelioma in Tissues and Effusions.

Signet ring cell mesothelioma; A diagnostic challenge

Pathology Research and Practice 2019 May 22 [Link] Wang H, Herath C Abstract Signet ring cell mesothelioma is a rare variant of epithelioid mesothelioma with limited cases published. It has a male predilection and most commonly occurs on pleura; it can also arise in the peritoneal cavity. The signet ring cell morphology can pose a […]

Comments Off on Signet ring cell mesothelioma; A diagnostic challenge

CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.

BMC Cancer 2019 May 28 [Link] Kettunen E, Savukoski S, Salmenkivi K, Böhling T, Vanhala E, Kuosma E, Anttila S, Wolff H Abstract BACKGROUND: Deletion of the CDKN2A locus is centrally involved in the development of several malignancies. In malignant pleural mesothelioma (MPM), it is one of the most frequently reported genomic alteration. MPM is […]

Comments Off on CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.